ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   


By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


SEARCH JOBS


 Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb Company
Employees:
Symbol: BMY
 





Collaborations

Gilead Sciences, Inc. 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys, Inc.  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co., Inc.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead Sciences, Inc. (Durham, NC) 

Phyton Biotech, Inc.  - Cancer

Gilead Sciences, Inc. (Seattle, WA) 





 Company News
Bristol-Myers Squibb Company (BMY) Submits New Drug Application To FDA For A Fixed-Dose Combination Tablet Of Atazanavir Sulfate With Cobicistat For People Living With HIV-1 4/14/2014 9:36:33 AM    More...
Bristol-Myers Squibb Company (BMY) Submits NDAs For Daclatasvir And Asunaprevir To The FDA For Hepatitis C Drugs 4/7/2014 6:50:56 AM    More...
Bristol-Myers Squibb Company (BMY) To Present Data For Daclatasvir In Multiple Investigational All-Oral Combinations Across Hepatitis C Genotypes At The International Liver Congress™ 3/24/2014 8:25:18 AM    More...
Five Prime Therapeutics, Inc. (FPRX), Bristol-Myers Squibb Company (BMY) Strike $350 Million Immuno-Oncology Pact 3/17/2014 6:54:22 AM    More...
Bristol-Myers Squibb Company (BMY)/Pfizer Inc. (PFE) Release: FDA Approves Eliquis® (Apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery 3/14/2014 1:13:59 PM    More...
Bristol-Myers Squibb Company (BMY) Announces Dividend 3/4/2014 8:57:28 AM    More...
Bristol-Myers Squibb Company (BMY) Announces Charitable Donation Of $1 Million To Support Immuno-Oncology Education For Patients And Caregivers 3/3/2014 8:20:47 AM    More...
Clinical Trials Initiated For A New Molecule Jointly Identified By IRIC And Bristol-Myers Squibb Company (BMY) 2/26/2014 9:35:18 AM    More...
FDA Approves Bristol-Myers Squibb Company (BMY)' Drug For Rare Fat Disorder 2/25/2014 7:22:51 AM    More...
Bristol-Myers Squibb Company (BMY) And Pfizer Inc. (PFE) Release: In a Subanalysis, Eliquis® (apixaban) Reduced The Risk of Stroke And Demonstrated Fewer Major Bleeding Events Versus Warfarin Consistently Across Age Groups, Including Older Patients With Nonvalvular Atrial Fibrillation 2/21/2014 9:13:43 AM    More...
12345678910...